

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



李 氏 大 藥 廠

## **Lee's Pharmaceutical Holdings Limited**

**李 氏 大 藥 廠 控 股 有 限 公 司 \***

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 950)**

### **SUPPLEMENTAL ANNOUNCEMENT REGARDING ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2019**

Reference is made to the annual report of Lee's Pharmaceutical Holdings Limited (the "**Company**") for the year ended 31 December 2019 (the "**Annual Report**"). Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as defined in the Annual Report.

In addition to the information provided in note 42 of the notes to the consolidated financial statements headed "Share Option Schemes" in the Annual Report, the Board would like to provide the following further information in relation to the share options granted to the directors and eligible employees of the Group under the 2002 Share Option Scheme and the New Share Option Scheme.

\* For identification purposes only

## MOVEMENT ON THE SHARE OPTIONS FOR THE YEAR ENDED 31 DECEMBER 2019

Date of share options granted	Vesting period	at 1 January 2019	No. of options			at 31 December 2019	Exercise period	Exercise price (HK\$)
			granted during the year	exercised during the year	lapsed during the year			
<b>Category I:</b>								
<b>Directors</b>								
30.12.2013	30.12.2013 to 29.06.2014	338,000	–	–	–	338,000	30.06.2014 to 29.12.2023	7.300
	30.12.2013 to 29.03.2015	538,000	–	–	–	538,000	30.03.2015 to 29.12.2023	7.300
31.03.2015	31.03.2015 to 29.09.2015	669,000	–	–	–	669,000	30.09.2015 to 30.03.2025	11.200
	31.03.2015 to 29.06.2016	669,000	–	–	–	669,000	30.06.2016 to 30.03.2025	11.200
31.03.2016	31.03.2016 to 29.09.2016	880,500	–	–	–	880,500	30.09.2016 to 30.03.2026	5.754
	31.03.2016 to 29.06.2017	880,500	–	–	–	880,500	30.06.2017 to 30.03.2026	5.754
13.04.2017	13.04.2017 to 12.10.2017	885,000	–	–	–	885,000	13.10.2017 to 12.04.2027	7.548
	13.04.2017 to 12.07.2018	885,000	–	–	–	885,000	13.07.2018 to 12.04.2027	7.548
13.04.2018	13.04.2018 to 12.10.2018	684,000	–	–	–	684,000	13.10.2018 to 12.04.2028	11.216
	13.04.2018 to 12.07.2019	684,000	–	–	–	684,000	13.07.2019 to 12.04.2028	11.216
15.04.2019	15.04.2019 to 14.10.2019	–	888,000	–	–	888,000	15.10.2019 to 14.04.2029	7.324
	15.04.2019 to 14.07.2020	–	888,000	–	–	888,000	15.07.2020 to 14.04.2029	7.324

Date of share options granted	Vesting period	No. of options				at 31 December 2019	Exercise period	Exercise price (HK\$)
		at 1 January 2019	granted during the year	exercised during the year	lapsed during the year			
<b>Category II:</b>								
<i>Employees</i>								
12.01.2010	12.01.2010 to 11.07.2010	120,000	-	-	-	120,000	12.07.2010 to 11.01.2020	2.200
	12.01.2010 to 11.04.2011	120,000	-	-	-	120,000	12.04.2011 to 11.01.2020	2.200
08.10.2012	08.10.2012 to 07.10.2013	400,000	-	-	-	400,000	08.10.2013 to 07.10.2022	4.996
	08.10.2012 to 07.10.2014	1,070,000	-	(190,000)	-	880,000	08.10.2014 to 07.10.2022	4.996
	08.10.2012 to 07.10.2015	2,030,000	-	(90,000)	-	1,940,000	08.10.2015 to 07.10.2022	4.996
05.04.2013	05.04.2013 to 04.10.2013	150,000	-	-	-	150,000	05.10.2013 to 04.04.2023	5.620
	05.04.2013 to 04.07.2014	150,000	-	-	-	150,000	05.07.2014 to 04.04.2023	5.620
30.12.2013	30.12.2013 to 29.12.2014	604,000	-	-	-	604,000	30.12.2014 to 29.12.2023	7.300
	30.12.2013 to 29.12.2015	620,000	-	-	-	620,000	30.12.2015 to 29.12.2023	7.300
	30.12.2013 to 29.12.2016	650,000	-	-	-	650,000	30.12.2016 to 29.12.2023	7.300
07.10.2014	07.10.2014 to 29.06.2015	300,000	-	-	-	300,000	30.06.2015 to 06.10.2024	10.340
	07.10.2014 to 02.10.2015	250,000	-	-	-	250,000	03.10.2015 to 06.10.2024	10.340
	07.10.2014 to 29.06.2016	300,000	-	-	-	300,000	30.06.2016 to 06.10.2024	10.340
	07.10.2014 to 02.10.2016	250,000	-	-	-	250,000	03.10.2016 to 06.10.2024	10.340
	07.10.2014 to 02.10.2017	250,000	-	-	-	250,000	03.10.2017 to 06.10.2024	10.340
03.10.2017	03.10.2017 to 02.10.2018	250,000	-	-	-	250,000	03.10.2018 to 02.10.2027	6.190
	03.10.2017 to 02.10.2019	250,000	-	-	-	250,000	03.10.2019 to 02.10.2027	6.190
	03.10.2017 to 02.10.2020	250,000	-	-	-	250,000	03.10.2020 to 02.10.2027	6.190
	03.10.2017 to 02.10.2021	500,000	-	-	-	500,000	03.10.2021 to 02.10.2027	6.190
	<b>Total</b>	<b>15,627,000</b>	<b>1,776,000</b>	<b>(280,000)</b>	<b>-</b>	<b>17,123,000</b>		

During the year ended 31 December 2019, the Company has granted share options to subscribe for a total of 1,776,000 ordinary shares of the Company under the New Share Option Scheme. The closing price of the shares of the Company immediately before the date on which the options were granted was HK\$7.310.

The above additional information does not affect any other information contained in the Annual Report. Save as disclosed in this announcement, the remaining contents of the Annual Report remain unchanged.

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 20 August 2020

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive directors of the Company, Mr. Simon Miles Ball is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.*